{"id":43397,"date":"2024-08-19T11:54:00","date_gmt":"2024-08-19T09:54:00","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=43397"},"modified":"2024-08-20T11:55:58","modified_gmt":"2024-08-20T09:55:58","slug":"busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/","title":{"rendered":"Busy week, Evaxion discuss partnership, FDA approval to Ascendis, DanCann positive EBITDA"},"content":{"rendered":"\n

NORDIC | BIOTECH & HEALTHCARE<\/strong> Your insights into listed Danish & Nordic biotech & healthcare stocks.<\/em><\/p>\n\n\n\n

The Kapital Partner Nordic healthcare index increased 1.9% amid in a news-filled week. There were many quarterly reports and business updates. Evaxion Biotech released one saying they have several ongoing partner discussions. Further, Dancann Pharma showed positive EBITDA in Q2 2024 for the first time, and Ascendis Pharma got FDA approval for YORVIPATH for the treatment of hyperparathyroidism. Finally, Zealand Pharma with new price targets.<\/strong><\/p>\n\n\n\n

12 of the 22 Danish biotech companies had a positive share price development the past week and 11 companies have had a positive share price performance year-to-date.<\/strong> Gubra is the best-performing Danish healthcare stock year-to-date with a 394% return and Xintela AB<\/strong> was the best Nordic healthcare investment last week.<\/strong> 4 Danish healthcare stocks with +100% YTD return.<\/strong><\/p>\n\n\n\n

\n
Register for the Nordic I Impact newsletter here.<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

Danish company news<\/strong><\/p>\n\n\n\n

Acarix<\/a><\/strong><\/p>\n\n\n\n

Acarix continues progress on reimbursement for CADScor System in US market (Link<\/a>)<\/p>\n\n\n\n

Acarix expands within US wellness exam market (Link<\/a>)<\/p>\n\n\n\n

Ascendis Pharma<\/a><\/strong><\/p>\n\n\n\n

FDA Approves YORVIPATH\u00ae (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults (Link<\/a>)<\/p>\n\n\n\n

Biosergen<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/p>\n\n\n\n

Cessatech<\/a><\/strong><\/p>\n\n\n\n

Cessatech extends its undrawn Loan Facility Agreement to DKK 10 million to support the forthcoming US launch of its lead program CT001<\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

CS Medica<\/a><\/strong><\/p>\n\n\n\n

CS MEDICA Q3 2023\/2024 Results: Strong Revenue Growth of 400% Despite Production Delays (Link<\/a>)<\/p>\n\n\n\n

 CS MEDICA Q3 2023\/2024: Growth Through Strategic Regulatory and Market Adaptations (Link<\/a>)<\/p>\n\n\n\n

Curasight<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/p>\n\n\n\n

DanCann Pharma<\/a><\/strong><\/p>\n\n\n\n

DanCann Pharma A\/S Publishes Q2-2024 Report: Record Revenue and First-Ever Positive EBITDA<\/em> (Link<\/a>)<\/p>\n\n\n\n

Quarterly CEO Reflection (Link<\/a>)<\/p>\n\n\n\n

Evaxion Biotech<\/a><\/strong><\/p>\n\n\n\n

Evaxion Announces Business Update and Second Quarter 2024 Financial Results<\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

ExpreS2ion<\/a><\/strong><\/p>\n\n\n\n

ExpreS2ion announces financial results for the second quarter of 2024<\/em> (Link<\/a>)<\/p>\n\n\n\n

Fluoguide<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Genmab<\/a><\/strong><\/p>\n\n\n\n

Genmab Announces Changes to its Executive Committee (Link<\/a>)<\/p>\n\n\n\n

Gubra<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Initiator Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

IO Biotech<\/a><\/strong><\/p>\n\n\n\n

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights<\/em><\/em> (Link)<\/p>\n\n\n\n

Pila Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Saniona<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Scandion Oncology<\/a><\/strong><\/p>\n\n\n\n

Scandion Oncology achieves Maximum Tolerated Dose for CORIST part 3<\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Scandion Oncology strengthens partnering outreach (Link<\/a>)<\/p>\n\n\n\n

SynAct Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/p>\n\n\n\n

ViroGates<\/a><\/strong><\/p>\n\n\n\n

ViroGates announces its half-year report for H1 2024: Revenue for the first half-year of 2024 falls behind the same period in 2023 due to lower activity among research customers<\/em> (Link<\/a>)<\/p>\n\n\n\n

Zealand Pharma<\/a><\/strong><\/p>\n\n\n\n

Zealand Pharma Announces Financial Results for the First Half of 2024<\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Goldman Sachs increased their price target to DKK 1,106, SEB to DKK 1,135, BTIG to DKK 1,050, while Danske Bank kept its price target at DKK 800 with a sell recommendation. The stock price is currently DKK 930.<\/p>\n\n\n\n

Y-mAbs Therapeutics<\/a><\/strong><\/p>\n\n\n\n

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments<\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

2cureX<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Share price development – Danish stocks<\/strong><\/p>\n\n\n\n

On average, the Danish biotech and healthcare stocks performed well, with a return of 2%. Evaxion Biotech<\/a><\/strong> rose 28% following Q2 results and a business update with several ongoing partner discussions. DanCann Pharma<\/a><\/strong> also had a good week after showing positive EBITDA for the first time. Ascendis Pharma<\/a><\/strong> got YORVIPATH approved by FDA as the first and only treatment for hypoparathyroidism in adults. Finally, it is also worth mentioning released its Q2 results and got several new price targets. Most of them are above the current share price with some upside left according to the analysts.<\/p>\n\n\n\n

The best stock year-to-date is <\/span>Gubra<\/a><\/strong> followed by <\/span><\/a><\/a>Pila Pharma<\/a><\/strong><\/strong><\/strong><\/strong> with 394% and 222% increases respectively after the first 7.5 months of trading. <\/span>CS Medica<\/a><\/strong>, <\/span>Zealand Pharma<\/a>,<\/strong> and <\/span><\/a>Acarix<\/a><\/strong><\/strong> have also made a 93% to 173% return year-to-date. <\/span>Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 35%. In other words, it has had a stellar performance.<\/strong><\/p>\n\n\n\n

Overview of share price development the past week, year-to-date, and the last twelve months<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Nordic Biotech & Healthcare Developments<\/mark><\/strong><\/p>\n\n\n\n

In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC)<\/strong> rose 1.9% to 71.02. The index has had a strong performance since the beginning of April and it has now surpassed the KPNGX index. In the past 12 months, the KPHC index has significantly underperformed relative to large caps, while it has outperformed the broader Nordic growth exchanges by approximately 5%.<\/p>\n\n\n\n

The index development for the KPHC index the past year<\/strong><\/p>\n\n\n\n

\"\"
The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.<\/sup><\/figcaption><\/figure>\n\n\n\n

39-53% in weekly return for the Nordic healthcare stocks<\/strong><\/p>\n\n\n\n

Xintela AB<\/a> (53%)<\/strong> expertise is found in regenerative medicine, as well as the treatment of cancer, articular cartilage damage, and brain tumors. The research is based on the development of protein molecules that have the capacity to sense changes in the surface of cells, which enables the identification of the stem cells that are about to develop into cartilage cells.<\/p>\n\n\n\n

Bavarian Nordic A\/S<\/a> (48%)<\/strong> specializes in the development, production and distribution of vaccines against infectious diseases in cancer treatment. In addition to its main activity, Bavarian Nordic also produces vaccines against serious diseases such as Ebola and cervical cancer. The rise in the stock price should be seen in the light of the current spread of mpox, where Bavarian Nordic owns JYNNEOS, the only FDA-approved mpox vaccine.<\/p>\n\n\n\n

Klaria Pharma Holding AB <\/a>(39%)<\/strong> is focused on developing and commercializing solutions in the therapy areas of migraine and cancer-related pain. The technology is based on the company’s drug-delivery platform, where the product consists of the alginate-based polymer film. The film attaches to the patient’s oral mucosa, which enables the distribution of pharmaceuticals in the body. The increase comes after approval for marketing a migraine product in Germany, Italy, and Spain.<\/p>\n\n\n\n

Sources: Refinitiv Eikon, Cision, Nordnet & company websites.<\/strong><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. The Kapital Partner Nordic healthcare index increased 1.9% amid in a news-filled week. There were many quarterly reports and business updates. Evaxion Biotech released one saying they have several ongoing partner discussions. Further, Dancann Pharma showed positive EBITDA in Q2 […]<\/p>\n","protected":false},"author":11,"featured_media":43132,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[29],"tags":[],"class_list":["post-43397","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investeringscases"],"acf":[],"yoast_head":"\nBusy week, Evaxion discuss partnership, FDA approval to Ascendis, DanCann positive EBITDA | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Busy week, Evaxion discuss partnership, FDA approval to Ascendis, DanCann positive EBITDA | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. The Kapital Partner Nordic healthcare index increased 1.9% amid in a news-filled week. There were many quarterly reports and business updates. Evaxion Biotech released one saying they have several ongoing partner discussions. Further, Dancann Pharma showed positive EBITDA in Q2 […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-19T09:54:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-20T09:55:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"724\" \/>\n\t<meta property=\"og:image:height\" content=\"418\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"Busy week, Evaxion discuss partnership, FDA approval to Ascendis, DanCann positive EBITDA\",\"datePublished\":\"2024-08-19T09:54:00+00:00\",\"dateModified\":\"2024-08-20T09:55:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/\"},\"wordCount\":959,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"articleSection\":[\"Investeringscases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/\",\"name\":\"Busy week, Evaxion discuss partnership, FDA approval to Ascendis, DanCann positive EBITDA | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"datePublished\":\"2024-08-19T09:54:00+00:00\",\"dateModified\":\"2024-08-20T09:55:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"width\":724,\"height\":418},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investeringscases\",\"item\":\"https:\/\/kapitalpartner.dk\/category\/investeringscases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Busy week, Evaxion discuss partnership, FDA approval to Ascendis, DanCann positive EBITDA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Busy week, Evaxion discuss partnership, FDA approval to Ascendis, DanCann positive EBITDA | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/","og_locale":"en_US","og_type":"article","og_title":"Busy week, Evaxion discuss partnership, FDA approval to Ascendis, DanCann positive EBITDA | Kapital Partner A\/S","og_description":"NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. The Kapital Partner Nordic healthcare index increased 1.9% amid in a news-filled week. There were many quarterly reports and business updates. Evaxion Biotech released one saying they have several ongoing partner discussions. Further, Dancann Pharma showed positive EBITDA in Q2 […]","og_url":"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2024-08-19T09:54:00+00:00","article_modified_time":"2024-08-20T09:55:58+00:00","og_image":[{"width":724,"height":418,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","type":"image\/jpeg"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"Busy week, Evaxion discuss partnership, FDA approval to Ascendis, DanCann positive EBITDA","datePublished":"2024-08-19T09:54:00+00:00","dateModified":"2024-08-20T09:55:58+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/"},"wordCount":959,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","articleSection":["Investeringscases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/","url":"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/","name":"Busy week, Evaxion discuss partnership, FDA approval to Ascendis, DanCann positive EBITDA | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","datePublished":"2024-08-19T09:54:00+00:00","dateModified":"2024-08-20T09:55:58+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","width":724,"height":418},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/busy-week-evaxion-discuss-partnership-fda-approval-to-ascendis-dancann-positive-ebitda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"Investeringscases","item":"https:\/\/kapitalpartner.dk\/category\/investeringscases\/"},{"@type":"ListItem","position":3,"name":"Busy week, Evaxion discuss partnership, FDA approval to Ascendis, DanCann positive EBITDA"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/43397"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=43397"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/43397\/revisions"}],"predecessor-version":[{"id":43398,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/43397\/revisions\/43398"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/43132"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=43397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=43397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=43397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}